Contact

It's the GeneMedi's summary page for Target/Biomarker Introduction of CD3E. The page also collects GeneMedi's different modalities and formats products for CD3E in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD3E target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is the CD3-epsilon polypeptide, which together with CD3-gamma, -delta and -zeta, and the T-cell receptor alpha/beta and gamma/delta heterodimers, forms the T-cell receptor-CD3 complex. This complex plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. The genes encoding the epsilon, gamma and delta polypeptides are located in the same cluster on chromosome 11. The epsilon polypeptide plays an essential role in T-cell development. Defects in this gene cause immunodeficiency. This gene has also been linked to a susceptibility to type I diabetes in women. [provided by RefSeq, Jul 2008]

Target IDGM-T87075
Target NameCD3E
Gene ID916
Gene Official NameCD3E
Gene AliasIMD18, T3E, TCRE
Protein Sub-locationTransmembrane Protein
CategoryTherapeutics Target, INN Index, Immuno-oncology Target


Pre-made CD3E-specific INN-index biosimilar (antibody&conjugates)-Mosunetuzumab, dafsolimab setaritox, Talquetamab, Visilizumab, Obrindatamab, Cibisatamab, Odronextamab, Runimotamab, Glofitamab, Ubamatamab, Etevritamab, Elranatamab, Vepsitamab, Plamotamab, Emerfetamab, Otelixizumab, Teplizumab, Pavurutamab, Voxalatamab, Tidutamab, Vibecotamab, Vixtimotamab, Epcoritamab, Acapatamab, Blinatumomab, Zolimomab, Gresonitamab, Pacanalotamab, Pasotuxizumab, Dafsolimab, catumaxomab, muromonab-CD3, Muromonab, Flotetuzumab, Eluvixtamab, Tarlatamab, Tepoditamab, Nivatrotamab, Alnuctamab, Solitomab, ertumaxomab, Teclistamab, Foralumab, Tebentafusp, Duvortuxizumab

Anti-CD3E therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.Products Name (INN Index)INN Name Previous Name Target FormatOrder
GMP-Bios-ab-356Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibodyMosunetuzumabCD3E;MS4A1/CD20Bispecific mAbINN mab
GMP-Bios-INN-790Pre-Made Dafsolimab Setaritox Biosimilar, Whole Mab Adc, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody Drug Conjugatedafsolimab setaritoxCD3EWhole mAb ADCINN mab
GMP-Bios-ab-546Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyTalquetamabGPRC5D;CD3EBispecific mAbINN mab
GMP-Bios-ab-622Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyVisilizumabCD3EWhole mAbINN mab
GMP-Bios-ab-386Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibodyObrindatamabCD276;CD3EBispecific scFv with Domain CrossoverINN mab
GMP-Bios-ab-104Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibodyCibisatamabCEACAM5;CD3EBispecific mAb with Domain CrossoverINN mab
GMP-Bios-ab-391Pre-Made Odronextamab biosimilar, Bispecific mAb, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibodyOdronextamabMS4A1/CD20;CD3EBispecific mAbINN mab
GMP-Bios-ab-500Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibodyRunimotamabERBB2/HER2;CD3EBispecific mAbINN mab
GMP-Bios-ab-248Pre-Made Glofitamab biosimilar, Bispecific mAb with Domain Crossover, Anti-CD3E;MS4A1/CD20 antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7therapeutic antibodyGlofitamabCD3E;MS4A1/CD20Bispecific mAb with Domain CrossoverINN mab
GMP-Bios-ab-705Pre-Made Ubamatamab biosimilar, Whole mAb, Anti-MUC16;CD3E Antibody: Anti-CA125;T3E/TCRE/IMD18 therapeutic antibodyUbamatamabMUC16;CD3EBispecific Whole mAbINN mab
GMP-Bios-ab-197Pre-Made Etevritamab biosimilar, Bispecific scFv, Anti-EGFR;CD3E Antibody: Anti-ERBB/ERRP/HER1/mENA/ERBB1/PIG61/NISBD2;T3E/TCRE/IMD18 therapeutic antibodyEtevritamabEGFR;CD3EBispecific scFvINN mab
GMP-Bios-ab-663Pre-Made Elranatamab biosimilar, Whole mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibodyElranatamabTNFRSF17;CD3EBispecific Whole mAbINN mab
GMP-Bios-ab-708Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibodyVepsitamabMUC17;CD3EBispecific scFv-scFv-scFcINN mab
GMP-Bios-ab-446Pre-Made Plamotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-MS4A1/CD20;CD3E Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7;T3E/TCRE/IMD18 therapeutic antibodyPlamotamabMS4A1/CD20;CD3EBispecific Mixed mAb and scFvINN mab
GMP-Bios-ab-176Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibodyEmerfetamabCD33;CD3EBispecific scFvINN mab
GMP-Bios-ab-414Pre-Made Otelixizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyOtelixizumabCD3EWhole mAbINN mab
GMP-Bios-ab-562Pre-Made Teplizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyTeplizumabCD3EWhole mAbINN mab
GMP-Bios-ab-433Pre-Made Pavurutamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibodyPavurutamabTNFRSF17;CD3EBispecific scFvINN mab
GMP-Bios-ab-709Pre-Made Voxalatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibodyVoxalatamabFOLH1/GCPII;CD3EBispecific Whole mAbINN mab
GMP-Bios-ab-570Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyTidutamabSSTR2;CD3EBispecific Mixed mAb and scFvINN mab
GMP-Bios-ab-619Pre-Made Vibecotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibodyVibecotamabIL3RA;CD3EBispecific Mixed mAb and scFvINN mab
GMP-Bios-ab-624Pre-Made Vixtimotamab biosimilar, Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)), Anti-CD3E;CD33 Antibody: Anti-T3E/TCRE/IMD18;p67/SIGLEC3/SIGLEC-3 therapeutic antibodyVixtimotamabCD3E;CD33Bispecific Homodimer (VK-VH-VL'-VH', Tandem diabody)INN mab
GMP-Bios-ab-189Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibodyEpcoritamabCD3E;MS4A1/CD20Bispecific mAbINN mab
GMP-Bios-ab-006Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibodyAcapatamabFOLH1/GCPII;CD3EBispecific scFvINN mab
GMP-Bios-ab-074Pre-Made Blinatumomab biosimilar, Bispecific T-Cell Engager, Anti-CD19;CD3E Antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyBlinatumomabCD19;CD3EBispecific T-Cell EngagerINN mab
GMP-Bios-ab-650Pre-Made Zolimomab biosimilar, Whole mAb, Anti-CD5 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyZolimomabCD5Whole mAbINN mab
GMP-Bios-ab-670Pre-Made Gresonitamab biosimilar, Whole mAb, Anti-CLDN18;CD3E Antibody: Anti-SFTA5/SFTPJ;T3E/TCRE/IMD18 therapeutic antibodyGresonitamabCLDN18;CD3EBispecific scFv-scFv-scFcINN mab
GMP-Bios-ab-421Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibodyPacanalotamabTNFRSF17;CD3EBispecific scFvINN mab
GMP-Bios-ab-429Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibodyPasotuxizumabFOLH1/GCPII;CD3EBispecific scFvINN mab
GMP-Bios-ab-130Pre-Made Dafsolimab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyDafsolimabCD3EWhole mAbINN mab
GMP-Bios-INN-772Pre-Made Catumaxomab Biosimilar, Bispecific, Anti-Cd3E; Epcam Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibodycatumaxomabCD3E;EPCAMBispecificINN mab
GMP-Bios-INN-921Pre-Made Muromonab-Cd3 3Iosimilar, Whole Mab, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibodymuromonab-CD3CD3EWhole  mAbINN mab
GMP-Bios-ab-360Pre-Made Muromonab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyMuromonabCD3EWhole mAbINN mab
GMP-Bios-ab-218Pre-Made Flotetuzumab biosimilar, Bispecific scFv with Crossover, Anti-IL3RA;CD3E Antibody: Anti-CD123/IL3RX/IL3RY/IL3RAY/hIL-3Ra;T3E/TCRE/IMD18 therapeutic antibodyFlotetuzumabIL3RA;CD3EBispecific scFv with CrossoverINN mab
GMP-Bios-ab-173Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibodyEluvixtamabCD33;CD3EBispecific scFvINN mab
GMP-Bios-ab-552Pre-Made Tarlatamab biosimilar, Bispecific scFv, Anti-DLL3;CD3E Antibody: Anti-SCDO1;T3E/TCRE/IMD18 therapeutic antibodyTarlatamabDLL3;CD3EBispecific scFvINN mab
GMP-Bios-ab-563Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibodyTepoditamabCLEC12A/CD371;CD3EBispecific mAbINN mab
GMP-Bios-ab-380Pre-Made Nivatrotamab biosimilar, Bispecific Mixed mAb and scFv, Anti-GD2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyNivatrotamabGD2;CD3EBispecific Mixed mAb and scFvINN mab
GMP-Bios-ab-018Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibodyAlnuctamabTNFRSF17;CD3EBispecific mAb with Domain CrossoverINN mab
GMP-Bios-ab-528Pre-Made Solitomab biosimilar, Bispecific scFv, Anti-EPCAM;CD3E Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1;T3E/TCRE/IMD18 therapeutic antibodySolitomabEPCAM;CD3EBispecific scFvINN mab
GMP-Bios-INN-845Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibodyertumaxomabCD3E;ERBB2BispecificINN mab
GMP-Bios-ab-557Pre-Made Teclistamab biosimilar, Bispecific mAb, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibodyTeclistamabTNFRSF17;CD3EBispecific mAbINN mab
GMP-Bios-ab-220Pre-Made Foralumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyForalumabCD3EWhole mAbINN mab
GMP-Bios-ab-555Pre-Made Tebentafusp biosimilar, scFv Fusion, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibodyTebentafuspCD3EscFv FusionINN mab
GMP-Bios-ab-161Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibodyDuvortuxizumabCD19;CD3EBispecific scFv with CrossoverINN mab



Pre-made anti-CD3E inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-CD3E benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD3E mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.Antibody NameFormatClassified by tagOrder
GM-Tg-hg-T87075-AbAnti-CD3E monoclonal antibodymabBiofunctional antibody, Therapeutics Target antibodymonoclonal antibody.




GENEMEDI
6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×